6 completed, 3 recruiting, 1 active not recruiting, 1 not yet recruiting. 6 Phase 2, 3 Phase 3, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 4 | 1 | Completed 1 |
Follow Factor 8 deficiency, acquired: new trials by email Literature Review of Factor 8 deficiency, acquired trials Research Report on Factor 8 deficiency, acquired
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A Bometase Alfa - Acquired Hemophilia A | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2026-08-01 | 2026-08-27 |
| A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea OBIZUR - Acquired Hemophilia A | Recruiting | Takeda | 9 | 2025-07-22 | 2026-09-11 | |
| Longitudinal Cohort of Thrombosis and Hemostasis Diseases Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura | Recruiting | Peking University People's Hospital | 3000 | 2024-11-01 | 2024-12-11 | |
| A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A Susoctocog Alfa (Genetical Recombination) - Acquired Hemophilia A | Recruiting | Takeda | 25 | 2024-06-10 | 2026-08-07 | |
| Emicizumab in Patients With Acquired Hemophilia A emicizumab - Acquired Hemophilia A | Phase 2 | Active not recruiting | University of Washington | 51 | 2022-08-31 | 2025-11-05 |
| Study of TAK-672 in Participants With Acquired Hemophilia A TAK-672 - Acquired Hemophilia A | Phase 2 / Phase 3 | Completed | Takeda | 5 | 2021-04-09 | 2024-12-02 |
| Emicizumab in Acquired Hemophilia A Emicizumab Injection - Hemophilia A, Acquired | Phase 2 | Completed | GWT-TUD GmbH | 47 | 2021-03-23 | 2023-01-09 |
| Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A Bortezomib, Rituximab - Acquired Hemophilia A | Phase 2 | Unknown | Peking Union Medical College Hospital | 22 | 2018-10-10 | 2018-11-23 |
| Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab Steroid, Rituximab, Cyclophosphamide - Acquired Hemophilia A | Phase 4 | Completed | Institute of Hematology & Blood Diseases Hospital, China | 66 | 2017-12-29 | 2026-02-11 |
| Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice OBIZUR - Acquired Hemophilia A | Completed | Baxalta now part of Shire | 50 | 2016-12-14 | 2022-07-21 | |
| Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A OBIZUR - Acquired Hemophilia A | Completed | Baxalta now part of Shire | 53 | 2015-12-30 | 2021-08-05 | |
| Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A OBI-1 - Acquired Hemophilia A | Phase 2 / Phase 3 | Completed | Baxalta now part of Shire | 29 | 2010-11-10 | 2021-05-13 |
| Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A Rituxan, prednisone - Hemophilia A | Phase 2 / Phase 3 | Terminated | Georgetown University | 2 | 2006-04-01 | 2017-02-10 |
| Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies OBI-1 - Acquired Hemophilia A | No longer available | Baxalta now part of Shire | 2021-05-05 |
Hemophilia A (3) · Blood Coagulation Disorders (1) · Coagulation Protein Disorders (1) · Disseminated Intravascular Coagulation (1) · Hematologic Diseases (1) · Hemophilia B (1) · Hemorrhagic Disorders (1) · Hemostatic Disorders (1) · Pulmonary Embolism (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Purpura, Thrombotic Thrombocytopenic (1) · Thrombophilia (1) · Thrombosis (1) · Thrombotic Microangiopathies (1)
Blood Coagulation Disorders, Inherited (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Hemic and Lymphatic Diseases (3) · Blood Coagulation Disorders (2) · Coagulation Protein Disorders (2) · Hematologic Diseases (2) · Hemorrhagic Disorders (2) · Autoimmune Diseases (1) · Blood Platelet Disorders (1) · Cardiovascular Diseases (1) · Cytopenia (1) · Embolism (1) · Embolism and Thrombosis (1) · Genetic Diseases, X-Linked (1)
Factor VIII (4) · Rituximab (3) · Adrenal Cortex Hormones (2) · emicizumab (2) · Bortezomib (1) · Cyclophosphamide (1) · Prednisone (1) · Steroids (1)
Baxalta now part of Shire (4) · Takeda (3) · Institute of Hematology & Blood Diseases Hospital, China (2) · GWT-TUD GmbH (1) · Georgetown University (1) · Peking Union Medical College Hospital (1) · Peking University People's Hospital (1) · University of Washington (1)
United States (5) · China (4) · Austria (2) · Germany (2) · Japan (2) · United Kingdom (2) · Canada (1) · France (1) · India (1) · Italy (1) · Netherlands (1) · South Korea (1)
Andreas Tiede, Prof. Dr. (1) · Craig Kessler, MD (1) · Lei Zhang (1) · Lei Zhang, MD (1) · Rebecca Kruse-Jarres, MD, MPH (1) · Tienan Zhu (1) · Xiao-Hui Zhang, MD (1)
PMID 39228858, PMID 25623166, PMID 29296693, PMID 37851608, PMID 37858328, PMID 40795229, PMID 42290320